Curtis Rambaran, MD, promoted to Chief Medical
Officer
Marie Wikstr�m Lindholm, PhD, promoted to Chief
Scientific Officer
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the
“Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced Curtis
Rambaran, MD, previously Silence’s Vice President, Head of Clinical
Science, has been promoted to Chief Medical Officer, and Marie
Wikstr�m Lindholm, PhD, previously Silence’s Senior Vice President,
Head of Molecular Design, has been promoted to Chief Scientific
Officer, effective immediately.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231201341026/en/
Curtis Rambaran, MD, Chief Medical
Officer at Silence Therapeutics plc (Photo: Business Wire)
“I want to congratulate Curtis and Marie on their well-deserved
promotions,” said Steven Romano, MD, Head of Research and
Development at Silence. “Both have been instrumental to our
clinical and scientific successes to date. Curtis’ broad experience
leading successful early and late-stage development programs
combined with his background in cardiovascular medicine will be
invaluable to Silence’s next phase of growth. With our expanding
mRNAi GOLD™ platform programs and commitment to advancing
scientific research, I am also looking forward to continuing to
collaborate closely with Marie. Her extensive work in
oligonucleotide therapeutics is impressive and we are very
fortunate to have her leading our efforts to innovate and further
expand our footprint as a global siRNA leader.”
About Curtis Rambaran, MD
Curtis Rambaran joined Silence Therapeutics as VP and Head of
the Clinical Science group in January 2021. He has 15 years’
experience in drug development across large pharma, medium sized
pharma and recently biotech, spanning early and late-stage programs
in cardiovascular, respiratory and rare diseases. Curtis joined the
Respiratory Translational Medicine team at GlaxoSmithKline (GSK) in
2009 developing first in human and experimental medicine studies
for novel oral and inhaled cardiopulmonary assets. He then moved to
late phase development to work on several cardiovascular outcome
studies (CVOTs) with novel anti-inflammatory MOA including LpPLA2
and p38 MAPK inhibitors. Following this, he became European Head of
Translational Medicine and Clinical Pharmacology at Daiichi Sankyo
UK, transitioning a year later to work with the New Jersey-based
team in the US, leading early development programs across
cardio-renal and rare diseases. This included human induced
pluripotent stem cells for heart failure, NaPi-IIb inhibition for
hyperphosphatemia in chronic kidney disease and an RNA antisense
oligonucleotide for Duchenne Muscular Dystrophy.
Prior to joining industry, Curtis received a prestigious
Wellcome Trust Cardiology Research Fellowship at King’s College
University of London, followed by a specialist training program in
Cardiovascular Medicine and Clinical Pharmacology at Guy’s & St
Thomas’ Hospital London, UK. Preceding this, he completed an
Internal Medicine residency in Yorkshire, UK after graduating with
a medical degree from the University of the West Indies. He has led
several academic-industry collaborations and published in
peer-reviewed journals on vascular structure and function, cardiac
safety, hypertension and clinical pharmacology.
About Marie Wikstr�m Lindholm, PhD
Marie Wikstr�m Lindholm joined Silence in December 2017. She has
more than 15 years’ experience with oligonucleotide therapeutics,
starting with Santaris Pharma A/S, Denmark, working on locked
nucleic acid (LNA) oligonucleotide drug discovery from molecule
design through in vitro screening, in vivo activity and metabolism
studies, and finally a role as lipid metabolism expert. When
Santaris was acquired by Roche in 2014, she was appointed Expert
Scientist in Discovery Technology and Head of Targeted Delivery of
oligonucleotide conjugates. She was also scientific coordinator for
the LNA work in two large EU-funded FP7 programs (AtheroBCell and
AtheroFlux). Before the transition to industry, she had an
international academic career in experimental cardiovascular
research starting with a PhD from Uppsala University. She has
authored over 60 patents and peer-reviewed scientific publications,
many in the fields of oligonucleotide drug design, safety, and
function.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include zerlasiran designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other securities laws, including
with respect to the Company’s cash runway and forecast operating
cash flow, the Company’s clinical and commercial prospects,
regulatory approvals of the Company’s product candidates, potential
partnerships or collaborations or payments under new and existing
collaborations, the initiation or completion of the Company’s
clinical trials and the anticipated timing or outcomes of data
reports from the Company’s clinical trials. These forward-looking
statements are not historical facts but rather are based on the
Company's current assumptions, beliefs, expectations, estimates and
projections about its industry. Words such as “anticipate,”
“expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” and
similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future
performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements, including those risks identified in
the Company’s most recent Admission Document and its Annual Report
on Form 20-F filed with the U.S. Securities and Exchange Commission
on March 15, 2023. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231201341026/en/
Silence Therapeutics plc Gem Hopkins, Head of IR and
Corporate Communications ir@silence-therapeutics.com Tel: +1 (646)
637-3208
Silence Therapeutics (NASDAQ:SLN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Silence Therapeutics (NASDAQ:SLN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024